In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: A population-based study (Taichung Community Health Study)

Annals of the Rheumatic Diseases

Volumn 67, Issue 3, 2008, Pages 432-433

  Lin, W Y ^a,b   Liu, C S ^a,b   Li, T C ^a,b,d   Lin, T ^a,b   Chen, W ^a,c,e   Chen, C C ^a,b   Li, C I ^a   Lin, C C ^a,b,d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE DISTRIBUTION; BODY FAT; BODY MASS; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; HEALTH PROGRAM; HOMEOSTASIS; HUMAN; HYPERURICEMIA; INSULIN RESISTANCE; LETTER; MEDICAL ETHICS; METABOLIC SYNDROME X; MICROALBUMINURIA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUTRITIONAL ASSESSMENT; OBESITY; PREVALENCE; PRIORITY JOURNAL; UNIVERSITY HOSPITAL; WAIST CIRCUMFERENCE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; FEMALE; HUMANS; HYPERURICEMIA; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY;

EID: 39549108111     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.073601     Document Type: Letter

References (10)

1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
2. Madsen TE, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Jackson JD, et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol 2005;25:45-9.
3. Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001;24:1758-63.
4. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES, et al. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004;53:1195-200.
5. Coutinho TA, Turner ST, Peyser PA, Bielak LF, Sheedy PF 2nd, Kullo IJ, et al. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens 2007;20:83-9.
6. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52.
7. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005;25:39-42.
8. Franks PW, Brage S, Luan J, Ekelund U, Rahman M, I. Farooqi IS, et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005;13:1476-84.
9. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
10. Lee SJ, Terkeltaub RA, Kavanaugh A. Recent developments in diet and gout. Curr Opin Rheumatol 2006;18:193-8.